Browse Discover Builder Rankings Pricing

Private market intelligence for investors, founders, and sales teams.

Product

Browse
Discover
List Builder
Rankings
Pricing

Developers

API Reference
API Keys

Company

About
Terms
Privacy
Contact

© 2026 Indexed.vc. All rights reserved.

Amicus Therapeutics: Company Profile & Funding | Indexed.vc

Amicus Therapeutics

IPO

Home - Amicus Therapeutics | Advancing Therapies to Treat Rare Diseases

Headquarters: Cranbury, New Jersey
Employees: 501–1000
Founded: 2002
Business Model: B2B
Website: amicusrx.com

Total Funding: $86.0M
Valuation: $4.8BDec 2025
Last Round: $55.0M Venture RoundJan 2006
Rounds: 4
Type: Public

About

Oral pharmacological chaperone protein therapies to address diseases that result from protein misfolding

LinkedIn X (Twitter)

Tech & App Stack

Tech & App Stack is available on paid plans

Upgrade to Silver or higher to reveal the full technology and app stack for any company.

Sign up to view funding chart

Create a free account to see funding visualizations and detailed round data.

Create Free Account

Funding History

AcquisitionDec 2025

Dec 2025

Debt FinancingDebt FinancingOct 2023

Oct 2023

Venture UnknownVenture RoundJan 2006

Jan 2006

Series CSeries CSep 2005

Sep 2005

Series BSeries BMay 2004

May 2004

SeedSeed RoundJul 2002

Jul 2002

Investors

Sign up to view investors

Create a free account to see which investors have funded this company.

Create Free Account

Similar Companies

Abogen Biosciences

China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.

Suzhou, China201–500Biotech, mRNA Therapeutics

Extension Round·$1.1B·Nov 2021

Eikon TherapeuticsIPO

Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...

Hayward, United States201–500Artificial Intelligence, Drug Discovery

Series D·$1.1B·Feb 2025

Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.

Tianjin, China5001–10000Healthcare, Biotech

Private Equity·$2.3B·Feb 2020

Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Life Sciences

Series D·$1.4B·Jun 2020

Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics

Corporate Round·$1.0B·Apr 2020

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech, Life Sciences

Series C·$955.0M·Sep 2024